Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Sci Rep ; 6: 38329, 2016 12 02.
Article in English | MEDLINE | ID: mdl-27910923

ABSTRACT

To understand the persistence of latently HIV-1 infected cells in virally suppressed infected patients, a number of in vitro models of HIV latency have been developed. In an attempt to mimic the in vivo situation as closely as possible, several models use primary cells and replication-competent viruses in combination with antiretroviral compounds to prevent ongoing replication. Latency is subsequently measured by HIV RNA and/or protein production after cellular activation. To discriminate between pre- and post-integration latency, integrase inhibitors are routinely used, preventing novel integrations upon cellular activation. Here, we show that this choice of antiretrovirals may still cause a bias of pre-integration latency in these models, as unintegrated HIV DNA can form and directly contribute to the levels of HIV RNA and protein production. We further show that the addition of reverse transcriptase inhibitors effectively suppresses the levels of episomal HIV DNA (as measured by 2-LTR circles) and decreases the levels of HIV transcription. Consequently, we show that latency levels described in models that only use integrase inhibitors may be overestimated. The inclusion of additional control conditions, such as 2-LTR quantification and the addition of reverse transcriptase inhibitors, is crucial to fully elucidate the actual levels of post-integration latency.


Subject(s)
HIV Integrase Inhibitors/pharmacology , HIV Protease Inhibitors/pharmacology , HIV-1/drug effects , Reverse Transcriptase Inhibitors/pharmacology , Viral Proteins/genetics , Virus Latency/drug effects , Alkynes , Benzoxazines/pharmacology , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/virology , Cyclopropanes , DNA, Viral/antagonists & inhibitors , DNA, Viral/biosynthesis , DNA, Viral/genetics , Genes, Reporter , Green Fluorescent Proteins/genetics , Green Fluorescent Proteins/metabolism , HIV Infections/drug therapy , HIV Infections/immunology , HIV Infections/virology , HIV-1/physiology , Humans , Lymphocyte Activation , Models, Biological , Nevirapine/pharmacology , Primary Cell Culture , Raltegravir Potassium/pharmacology , Ritonavir/pharmacology , Viral Proteins/antagonists & inhibitors , Viral Proteins/biosynthesis , Virus Integration/drug effects , Virus Replication/drug effects
2.
AIDS Rev ; 18(4): 171-183, 2016.
Article in English | MEDLINE | ID: mdl-27438577

ABSTRACT

Due to the scarcity of HIV-1 latently infected cells in patients, in vitro primary latency models are now commonly used to study the HIV-1 reservoir. To this end, a number of experimental systems have been developed. Most of these models differ based on the nature of the primary CD4+ T-cell type, the used HIV strains, activation methods, and latency assessment strategies. Despite these differences, most models share some common characteristics. Here, we provide a systematic review covering the primary HIV latency models that have been used to date with the aim to compare these models and identify minimal requirements for such experiments. A systematic search on PubMed and Web of Science databases generated a short list of 17 unique publications that propose new in vitro latency models. Based on the described methods, we propose and discuss a generalized workflow, visualizing all the necessary steps to perform such an in vitro study, with the key choices and validation steps that need to be made; from cell type selection until the model readout.


Subject(s)
HIV Infections/virology , HIV-1/physiology , Virus Latency/physiology , Humans , Models, Biological , T-Lymphocytes/physiology , T-Lymphocytes/virology
3.
AIDS Res Hum Retroviruses ; 32(2): 187-93, 2016 02.
Article in English | MEDLINE | ID: mdl-26171776

ABSTRACT

HIV-1 latently infected cells in vivo can be found in extremely low frequencies. Therefore, in vitro cell culture models have been used extensively for the study of HIV-1 latency. Often, these in vitro systems utilize defective viruses. Defective viruses allow for synchronized infections and circumvent the use of antiretrovirals. In addition, replication-defective viruses cause minimal cytopathicity because they fail to spread and usually do not encode env or accessory genes. On the other hand, replication-competent viruses encode all or most viral genes and better recapitulate the nuances of the viral replication cycle. The study of latency with replication-competent viruses requires the use of antiretroviral drugs in culture, and this mirrors the use of antiretroviral treatment (ART) in vivo. We describe a model that utilizes cultured central memory CD4(+) T cells and replication-competent HIV-1. This method generates latently infected cells that can be reactivated using latency reversing agents in the presence of antiretroviral drugs. We also describe a method for the removal of productively infected cells prior to viral reactivation, which takes advantage of the downregulation of CD4 by HIV-1, and the use of a GFP-encoding virus for increased throughput.


Subject(s)
CD4-Positive T-Lymphocytes/virology , HIV-1/physiology , Leukocytes, Mononuclear/virology , Models, Biological , Virus Activation/physiology , Virus Latency/physiology , CD4-Positive T-Lymphocytes/immunology , Cells, Cultured , Down-Regulation , Flow Cytometry , Green Fluorescent Proteins/genetics , HIV Infections/virology , Humans , Virus Replication/physiology
4.
Elife ; 4: e09115, 2015 Oct 06.
Article in English | MEDLINE | ID: mdl-26439007

ABSTRACT

Persistent reservoirs remain the major obstacles to achieve an HIV-1 cure. Prolonged early antiretroviral therapy (ART) may reduce the extent of reservoirs and allow for virological control after ART discontinuation. We compared HIV-1 reservoirs in a cross-sectional study using polymerase chain reaction-based techniques in blood and tissue of early-treated seroconverters, late-treated patients, ART-naïve seroconverters, and long-term non-progressors (LTNPs) who have spontaneous virological control without treatment. A decade of early ART reduced the total and integrated HIV-1 DNA levels compared with later treatment initiation, but not reaching the low levels found in LTNPs. Total HIV-1 DNA in rectal biopsies did not differ between cohorts. Importantly, lower viral transcription (HIV-1 unspliced RNA) and enhanced immune preservation (CD4/CD8), reminiscent of LTNPs, were found in early compared to late-treated patients. This suggests that early treatment is associated with some immunovirological features of LTNPs that may improve the outcome of future interventions aimed at a functional cure.


Subject(s)
Anti-Retroviral Agents/therapeutic use , Antiretroviral Therapy, Highly Active/methods , HIV Infections/drug therapy , HIV Infections/epidemiology , HIV-1/isolation & purification , Viral Load , Adult , Blood/virology , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Proviruses/isolation & purification , Rectum/virology , Secondary Prevention , Treatment Outcome
5.
J Antimicrob Chemother ; 70(12): 3311-6, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26324076

ABSTRACT

OBJECTIVES: Whether ART regimens differ in their propensity to allow persistent HIV-1 detection remains unclear. To investigate this, we performed a cross-sectional study to characterize HIV-1 persistence in peripheral blood during suppressive therapy with NRTIs plus a PI or nevirapine. METHODS: Residual plasma HIV-1 RNA was quantified by real-time PCR. Cell-associated proviral total HIV-1 DNA, unspliced and multiply spliced HIV-1 RNA and 2-long terminal repeat (2-LTR) circles were quantified by digital PCR. RESULTS: Comparing PI with nevirapine recipients, residual plasma HIV-1 RNA detection rates were 47/80 (58.8%) versus 37/81 (45.7%), with median (IQR) levels of 4 (3-8) versus 4 (3-7) copies/mL (P = 0.207); detection was less likely with longer duration of suppressive ART (P = 0.020), independently of treatment. HIV-1 DNA was detected in all patients, with median levels of 2.3 (IQR 2.0-2.7) versus 2.5 (IQR 2.1-2.7) log10 copies/10(6) PBMCs, respectively; HIV-1 DNA levels were associated with pre-ART viral load (P = 0.004) and with residual HIV-1 RNA (P = 0.034), unspliced HIV-1 RNA (P = 0.001) and 2-LTR circles (P = 0.005), independently of treatment. CONCLUSIONS: No significant differences were revealed in levels of residual plasma HIV-1 RNA, total HIV-1 DNA or intracellular markers of ongoing virus replication (unspliced and multiply spliced HIV-1 RNA and 2-LTR circles) between treatment groups.


Subject(s)
Anti-HIV Agents/therapeutic use , Antiretroviral Therapy, Highly Active/methods , DNA, Viral/blood , HIV Infections/drug therapy , HIV-1/isolation & purification , RNA, Viral/blood , Viral Load , Adult , Cross-Sectional Studies , Female , HIV Protease Inhibitors/therapeutic use , Humans , Male , Middle Aged , Nevirapine/therapeutic use , Polymerase Chain Reaction , Treatment Outcome
6.
Anal Bioanal Chem ; 407(19): 5827-34, 2015 Jul.
Article in English | MEDLINE | ID: mdl-26022094

ABSTRACT

Digital PCR is rapidly gaining interest in the field of molecular biology for absolute quantification of nucleic acids. However, the first generation of platforms still needs careful validation and requires a specific methodology for data analysis to distinguish negative from positive signals by defining a threshold value. The currently described methods to assess droplet digital PCR (ddPCR) are based on an underlying assumption that the fluorescent signal of droplets is normally distributed. We show that this normality assumption does not likely hold true for most ddPCR runs, resulting in an erroneous threshold. We suggest a methodology that does not make any assumptions about the distribution of the fluorescence readouts. A threshold is estimated by modelling the extreme values in the negative droplet population using extreme value theory. Furthermore, the method takes shifts in baseline fluorescence between samples into account. An R implementation of our method is available, allowing automated threshold determination for absolute ddPCR quantification using a single fluorescent reporter.


Subject(s)
Polymerase Chain Reaction/methods , Fluorescence
7.
PLoS One ; 10(4): e0123525, 2015.
Article in English | MEDLINE | ID: mdl-25874872

ABSTRACT

Abacavir is a nucleoside reverse transcriptase inhibitor used as part of combination antiretroviral therapy in HIV-1-infected patients. Because this drug can cause a hypersensitivity reaction that is correlated with the presence of the HLA-B*57:01 allotype, screening for the presence of HLA-B*57:01 is recommended before abacavir initiation. Different genetic assays have been developed for HLA-B*57:01 screening, each with specific sensitivity, turnaround time and assay costs. Here, a new real-time PCR (qPCR) based analysis is described and compared to sequence specific primer PCR with capillary electrophoresis (SSP PCR CE) on 149 patient-derived samples, using sequence specific oligonucleotide hybridization combined with high resolution SSP PCR as gold standard. In addition to these PCR based methods, a complementary approach was developed using flow cytometry with an HLA-B17 specific monoclonal antibody as a pre-screening assay to diminish the number of samples for genetic testing. All three assays had a maximum sensitivity of >99. However, differences in specificity were recorded, i.e. 84.3%, 97.2% and >99% for flow cytometry, qPCR and SSP PCR CE respectively. Our data indicate that the most specific and sensitive of the compared methods is the SSP PCR CE. Flow cytometry pre-screening can substantially decrease the number of genetic tests for HLA-B*57:01 typing in a clinical setting.


Subject(s)
Dideoxynucleosides/administration & dosage , Drug Hypersensitivity/prevention & control , HIV Infections/drug therapy , HLA-B Antigens/genetics , Real-Time Polymerase Chain Reaction/methods , Reverse Transcriptase Inhibitors/administration & dosage , Alleles , Antiretroviral Therapy, Highly Active , DNA Primers/chemical synthesis , DNA Primers/genetics , Dideoxynucleosides/adverse effects , Drug Hypersensitivity/etiology , Drug Hypersensitivity/genetics , Drug Hypersensitivity/immunology , Electrophoresis, Capillary , Flow Cytometry , Gene Expression , Genetic Testing/methods , HIV Infections/genetics , HIV Infections/immunology , HIV Infections/virology , HIV-1/drug effects , HIV-1/enzymology , HIV-1/genetics , HLA-B Antigens/immunology , Humans , Nucleic Acid Hybridization/methods , Reverse Transcriptase Inhibitors/adverse effects , Sensitivity and Specificity
8.
J Clin Microbiol ; 53(2): 699-701, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25502524

ABSTRACT

Episomal HIV-1 two-long terminal repeat (2-LTR) circles are considered markers for ongoing viral replication. Two sample processing procedures were compared to accurately quantify 2-LTR in patients by using droplet digital PCR (ddPCR). Here, we show that plasmid isolation with a spiked non-HIV plasmid for normalization enables more accurate 2-LTR quantification than genomic DNA isolation.


Subject(s)
DNA, Viral/isolation & purification , HIV-1/genetics , Plasmids/isolation & purification , Polymerase Chain Reaction/methods , Terminal Repeat Sequences , DNA, Viral/analysis , Humans , Plasmids/analysis
9.
J Int AIDS Soc ; 17(4 Suppl 3): 19674, 2014.
Article in English | MEDLINE | ID: mdl-25397424

ABSTRACT

INTRODUCTION: In HIV-infected patients on combination antiretroviral therapy (cART), the detection of episomal HIV 2-LTR circles is a potential marker for ongoing viral replication. Quantification of 2-LTR circles is based on quantitative PCR or more recently on digital PCR assessment, but is hampered due to its low abundance. Sample pre-PCR processing is a critical step for 2-LTR circles quantification, which has not yet been sufficiently evaluated in patient derived samples. MATERIALS AND METHODS: We compared two sample processing procedures to more accurately quantify 2-LTR circles using droplet digital PCR (ddPCR). Episomal HIV 2-LTR circles were either isolated by genomic DNA isolation or by a modified plasmid DNA isolation, to separate the small episomal circular DNA from chromosomal DNA. This was performed in a dilution series of HIV-infected cells and HIV-1 infected patient derived samples (n=59). Samples for the plasmid DNA isolation method were spiked with an internal control plasmid. RESULTS: Genomic DNA isolation enables robust 2-LTR circles quantification. However, in the lower ranges of detection, PCR inhibition caused by high genomic DNA load substantially limits the amount of sample input and this impacts sensitivity and accuracy. Moreover, total genomic DNA isolation resulted in a lower recovery of 2-LTR templates per isolate, further reducing its sensitivity. The modified plasmid DNA isolation with a spiked reference for normalization was more accurate in these low ranges compared to genomic DNA isolation. A linear correlation of both methods was observed in the dilution series (R2=0.974) and in the patient derived samples with 2-LTR numbers above 10 copies per million peripheral blood mononuclear cells (PBMCs), (R2=0.671). Furthermore, Bland-Altman analysis revealed an average agreement between the methods within the 27 samples in which 2-LTR circles were detectable with both methods (bias: 0.3875±1.2657 log10). CONCLUSIONS: 2-LTR circles quantification in HIV-infected patients proved to be more accurate with a modified plasmid DNA isolation procedure compared to total genomic DNA isolation. This method enables the processing of more blood cells, thus enhancing quantification accuracy and sensitivity. An improved quantification of 2-LTR circles will contribute to the better understanding of ongoing replication in the HIV reservoir of patients on cART.

10.
J Int AIDS Soc ; 17(4 Suppl 3): 19823, 2014.
Article in English | MEDLINE | ID: mdl-25397567

ABSTRACT

INTRODUCTION: The source and significance of residual plasma HIV-1 RNA detection during suppressive ART remain controversial. It has been proposed that nevirapine (NVP)-based regimens achieve a greater HIV-1 RNA suppression than regimens containing a protease inhibitor (PI). The aim of this study was to compare the effect of receiving NVP- vs PI-based ART on the virological markers of HIV persistence in peripheral blood. MATERIAL AND METHODS: The study population comprised 161 HIV-1 infected patients receiving either NVP-based (n=81) or PI-based (n=80) ART and showing a HIV-1 RNA load stably suppressed <40 copies/mL for median of 5.2 years (IQR 2.2-8.0). Residual viraemia was detected by real-time PCR with 50% and 95% detection thresholds of 1 and 3 HIV-1 RNA copies/mL, respectively. Cell-associated (CA) unspliced HIV-1 RNA, total HIV-1 DNA and 2 LTR circles were quantified in peripheral blood mononuclear cells (PBMCs) using droplet digital PCR. Groups were compared by standard non-parametric tests; factors associated with HIV-1 detection were analyzed by univariate regression analysis and generalized linear models (SPSS® V22 and Rstudio). RESULTS: Plasma HIV-1 RNA was detected in 37/81 (45.7%) and 47/80 (58.8%) subjects on NVP- and PI-based ART, with median (IQR) levels of 5 (3-6) and 5 (3-8) copies/mL, respectively. HIV-1 RNA detection was associated with shorter duration of suppressive ART regardless of treatment arm (p=0.007), and lower CD4 nadir (p=0.015). HIV-1 DNA levels were median 282 (120-484) and 213 (87-494) copies/106 PBMCs in the two groups respectively, and were lowest (<100 copies/106 PBMCs) in subjects with lower plasma HIV-1 RNA (p=0.049), CA unspliced HIV-1 RNA (p=0.0001), 2 LTR circles (p=0.005) and pre-ART HIV-1 RNA load (p=0.0001). CONCLUSIONS: In this comprehensive characterization of patients on long-term suppressive ART, we did not observe evidence for a greater suppressive activity of NVP-based over PI-based therapy on plasma and intracellular markers of virus persistence. Overall excellent correlation was observed between the markers, allowing the identification of a subset of treated patients with low HIV-1 expression as an important cohort for future HIV cure studies.

11.
Retrovirology ; 11: 70, 2014 Aug 21.
Article in English | MEDLINE | ID: mdl-25142072

ABSTRACT

The central memory T cell (TCM) model forms a unique HIV-1 latency model based on primary cells that closely resemble in vivo TCM. The virus employed in this model is based on an engineered vector incapable of replication after initial infection. We show that despite this strategy, replication competent viral particles are released into the culture medium due to recombination between overlapping sequences of the env deleted HIV genome that is co-transfected with intact env. This finding emphasizes the need for careful data analysis and interpretation if similar constructs are employed and urges for additional caution during laboratory work.


Subject(s)
HIV Infections/virology , HIV-1/physiology , Virus Latency , Virus Replication/genetics , CD4-Positive T-Lymphocytes/virology , DNA, Viral/genetics , Genes, env , Genetic Vectors/genetics , HIV-1/genetics , Humans
12.
Anal Biochem ; 439(2): 201-3, 2013 Aug 15.
Article in English | MEDLINE | ID: mdl-23664868

ABSTRACT

Digital polymerase chain reaction (PCR) is an emerging absolute quantification method based on the limiting dilution principle and end-point PCR. This methodology provides high flexibility in assay design without influencing quantitative accuracy. This article describes an assay to quantify HIV DNA that targets a highly conserved region of the HIV-1 genome that hampers optimal probe design. To maintain high specificity and allow probe binding and hydrolysis of a probe with low melting temperature, a two-stage touchdown PCR was designed with a first round of amplification at high temperature and a subsequent round at low temperature to allow accumulation of fluorescence.


Subject(s)
Conserved Sequence , Genome, Viral , HIV-1/genetics , Polymerase Chain Reaction/methods , RNA, Viral/genetics , Base Sequence
SELECTION OF CITATIONS
SEARCH DETAIL
...